MONTEGO BAY, Jamaica — The drug manufacturer MannKind has been burning through millions of dollars each month. It only has 3,000 patients taking its sole product, an inhalable form of insulin. It recently said it doesn’t have enough cash to get to the end of this year.

So why, then, is the company sponsoring a reality TV show filmed here in this tropical resort town?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Tropical resort? Contract signing? So much happy horse sh*t. These T2s have already violated their own contracts with their bodies by allowing themselves to tip the scales north of BMI 35 fron a lifetime of gluttony. As a diabetic my insurance covers 10 HOURS of diabetes education. But it is delivered in a sterile classroom, drinking complimentary bottles of zero calorie water instead of watching TV from a tropical island while getting in the mood by secretly sipping pina coladas loaded with sugar. These “contracts” are a gimmick, like the ones the junkies sign with their pain med doc aka dope dealer with a medical license.

  • Absolutely disgusting reporting aimed at minimizing what this company has been able to accomplish and the patients that have come to depend on this truly innovative diabetes medicine. Why spend time on ONLY the negative and not even mention how patients are reporting life best A1C numbers while significantly improving their daily lives through inhaled insulin. Very pathetic, Rebecca.

  • Very well said, i wish them well also. This wanna be reporter seems to have it out for the show and the product. I found this very sad, so many people benefit from Afrezza and if they want to sponsor something to help get the word out so what, big pharma spend billions to market and this small company is trying to compete, whats wrong with that.

  • Inhalable insulin, even if no better medically than injected, would be a TREMENDOUS benefit to many people (and would get some people to be compliant who would NOT be otherwise) . Wishing them well . . . it would be a shame to see something so beneficial die on the vine …

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy